Clinical Artificial Intelligence-based Diagnostics

AI in Clinical Research

28 February 2024
Technical details
Clinical trials are challenging, lengthy, and often very costly. The likelihood of success for innovative drugs in clinical trials is typically only a few percent. However, artificial intelligence (AI) can significantly assist in clinical research, particularly in the following areas:
  1. Patient selection: AI algorithms can analyze medical data to identify patients who meet the study criteria.
  2. Health monitoring: AI can track patients’ health parameters in real time, enabling early detection of potential issues.
  3. Results analysis: Algorithms process vast amounts of data, aiding in the analysis of trial outcomes.
  4. Dose optimization: AI can help optimize drug dosages, considering individual patient characteristics.
  5. Decision support: Algorithms assist in evaluating treatment effectiveness and deciding when to conclude a clinical trial.
More and more pharmaceutical companies and healthcare institutions such as hospitals use AI for a wide range of activities, ranging from imaging diagnostics, oncological diagnostics based on the analysis of the entire genome, to the design of clinical trials.
An example of such artificial intelligence is a program created at Ben Gurion University in Be’er Sheva, which is used in clinical trials for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. It helps to better group patients, develop statistical data, and indicate possible connections with other diseases and medications. The AI system is also able to perform predictive analysis (forecast) of disease progression in patients.
Similar need has been recognized by the Medical Research Agency in Poland, which has established Regional Centers for Digital Medicine (RCDM). RCDMs operate alongside clinical research units. Their goal is to build the necessary infrastructure, personnel, and systems to increase scientific research, with a particular focus on clinical studies. Additionally, they aim to create favorable conditions for the development of innovative technologies, including pharmaceutical and IT solutions, applicable in healthcare.
The 18 emerging RCDMs will be part of the Digital Medicine Centers Network, with the Medical Research Agency playing a central role. These centers will serve real-time data analysis, support clinical research, and enhance hospital care through digital solutions. They will also engage in retrospective analysis. Start of action by Regional Centers for Digital Medicine in Poland are planned for the fourth quarter of 2025. As part of RCDM.
The goal of Centers intend to acquire (or design) a range of analytical and statistical tools that leverage artificial intelligence algorithms, including machine learning. The development of these tools will serve as an excellent test of implementing solutions offered by companies conducting research in artificial intelligence.
You can find more information about the RCDM project materials at this link: ABM RCDM Project